Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

Publikation

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

Wissenschaftlicher Artikel/Review - 10.02.2012

Carbajo-Lozoya Javier, Müller Marcel A, Kallies Stephan, Thiel Volker, Drosten Christian, von Brunn Albrecht

Zitation

Carbajo-Lozoya J, Müller M, Kallies S, Thiel V, Drosten C, von Brunn A. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. Virus Res 2012; 165:112-7.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Virus Res 2012; 165

Veröffentlichungsdatum

10.02.2012

eISSN (Online)

1872-7492

Seiten

112-7

Kurzbeschreibung/Zielsetzung

Recent research has shown that Coronavirus (CoV) replication depends on active immunophilin pathways. Here we demonstrate that the drug FK506 (Tacrolimus) inhibited strongly the growth of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E at low, non-cytotoxic concentrations in cell culture. As shown by plaque titration, qPCR, Luciferase- and green fluorescent protein (GFP) reporter gene expression, replication was diminished by several orders of magnitude. Knockdown of the cellular FK506-binding proteins FKBP1A and FKBP1B in CaCo2 cells prevented replication of HCoV-NL63, suggesting the requirement of these members of the immunophilin family for virus growth.